PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1781961
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1781961
Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.
Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.
Viral Vector Vaccines Market- Market Dynamics
Increasing prevalence of infectious diseases to propel market demand
The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.
Viral Vector Vaccines Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)
Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024
Based on Type segmentation, adenovirus was the leading Type in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.
The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.
The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.
Viral Vector Vaccines Market- Geographical Insights
The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.
Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.
In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.